Publications by authors named "Maria Sanz-Jardon"
Subsequent biologic and targeted synthetic disease modifying anti rheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria: a survival analysis.
Marta Novella-Navarro Virginia Ruiz-Esquide Natalia López-Juanes Chafik Alejandro Chacur Irene Monjo-Henry
Clin Rheumatol
September 2024
Article Synopsis
- The study evaluates the effectiveness and survival rates of various biologic and targeted-synthetic drugs for patients with difficult-to-treat rheumatoid arthritis (D2TRA).
- Out of 122 patients analyzed, 61.5% continued treatment with better survival linked to drugs like rituximab, while others like abatacept showed poorer survival rates.
- Key factors influencing treatment discontinuation included the choice of the drug and higher Disease Activity Score (DAS28) six months post-treatment initiation.
Mobile health technology holds great promise for the clinical management of patients with chronic disease. However, evidence on the implementation of projects involving digital health solutions in rheumatology is scarce. We aimed to study the feasibility of a hybrid (virtual and face-to-face) monitoring strategy for personalized care in rheumatoid arthritis (RA) and spondyloarthritis (SpA).
View Article and Find Full Text PDF